Royalty Pharma (RPRX) Consolidated Net Income (2019 - 2026)

Royalty Pharma has disclosed Consolidated Net Income across 8 years of filings, most recently posting $81.5 million for Q2 2026.

• In Q2 2026, Consolidated Net Income fell 12.04% year-over-year to $81.5 million; the TTM figure through Jun 2026 stood at $1.3 billion (down 19.06% YoY), while the FY2025 annual figure was $1.3 billion, changed 0.5% from the prior year.
• Consolidated Net Income came in at $81.5 million for Q2 2026 at Royalty Pharma, down from $468.3 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $806.4 million in Q3 2024 to a low of -$610.0 million in Q4 2022.
• Average Consolidated Net Income over 5 years is $285.4 million, with a median of $342.8 million recorded in 2023.
• Year-over-year, Consolidated Net Income tumbled 1236.61% in 2022 and jumped 10266.93% in 2025.
• Over 5 years, Consolidated Net Income stood at -$610.0 million in 2022, then jumped by 217.63% to $717.6 million in 2023, then tumbled by 53.41% to $334.4 million in 2024, then increased by 6.45% to $355.9 million in 2025, then slumped by 77.11% to $81.5 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were $81.5 million in Q2 2026, $468.3 million in Q1 2026, and $355.9 million in Q4 2025.